[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inmune Bio Inc (INMB)

Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,264
  • Shares Outstanding, K 26,585
  • Annual Sales, $ 50 K
  • Annual Income, $ -45,930 K
  • EBIT $ -43 M
  • EBITDA $ -43 M
  • 60-Month Beta 0.97
  • Price/Sales 903.89
  • Price/Cash Flow N/A
  • Price/Book 2.30

Options Overview Details

View History
  • Implied Volatility 178.83% (-44.58%)
  • Historical Volatility 72.90%
  • IV Percentile 33%
  • IV Rank 14.20%
  • IV High 764.52% on 03/27/26
  • IV Low 81.87% on 08/14/25
  • Expected Move (DTE 10) 0.0510 (2.93%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 214
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 3,961
  • Open Int (30-Day) 4,699
  • Expected Range 1.6890 to 1.7910

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +249,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +45.00%
on 06/11/26
1.8500 -5.95%
on 07/07/26
+0.4800 (+38.10%)
since 06/05/26
3-Month
1.1550 +50.65%
on 04/10/26
1.8500 -5.95%
on 07/07/26
+0.4700 (+37.01%)
since 04/07/26
52-Week
1.0900 +59.63%
on 03/31/26
3.2440 -46.36%
on 07/28/25
-0.5600 (-24.35%)
since 07/07/25

Most Recent Stories

More News
INmune Bio CEO to Speak at Maxim Growth Summit

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inmune Bio...

INMB : 1.7400 (+4.50%)
OmniScience and INmune Bio Collaborate to Enhance Clinical Trial Decision-Making with Vivo GenAI Platform

OmniScience and INmune Bio partner to enhance decision-making in Alzheimer's clinical trials using Vivo's genAI-powered platform.Quiver AI SummaryOmniScience and INmune Bio have announced a partnership...

INMB : 1.7400 (+4.50%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 1.9200 (-2.54%)
LLY : 1,235.56 (+2.96%)
INMB : 1.7400 (+4.50%)
XBI : 163.87 (+1.90%)
BIIB : 205.70 (-1.32%)
SAVA : 2.38 (+12.26%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...

ANVS : 1.9200 (-2.54%)
LLY : 1,235.56 (+2.96%)
INMB : 1.7400 (+4.50%)
XBI : 163.87 (+1.90%)
BIIB : 205.70 (-1.32%)
SAVA : 2.38 (+12.26%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 1.9200 (-2.54%)
LLY : 1,235.56 (+2.96%)
INMB : 1.7400 (+4.50%)
XBI : 163.87 (+1.90%)
BIIB : 205.70 (-1.32%)
SAVA : 2.38 (+12.26%)
INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

INMB earnings call for the period ending June 30, 2022.

INMB : 1.7400 (+4.50%)
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Company to Host Conference Call Today, August 3, at 4:30pm ET...

INMB : 1.7400 (+4.50%)
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....

INMB : 1.7400 (+4.50%)
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease

Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...

INMB : 1.7400 (+4.50%)

Business Summary

INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing...

See More

Key Turning Points

3rd Resistance Point 2.1900
2nd Resistance Point 2.0200
1st Resistance Point 1.8800
Last Price 1.7400
1st Support Level 1.5700
2nd Support Level 1.4000
3rd Support Level 1.2600

See More

52-Week High 3.2440
Fibonacci 61.8% 2.4212
Fibonacci 50% 2.1670
Fibonacci 38.2% 1.9128
Last Price 1.7400
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.